Apoptosis in cancer: From pathogenesis to treatment

Journal of Experimental and Clinical Cancer Research

Volumn 30, Issue 1, 2011, Pages

  Wong, Rebecca S Y ^a  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

Author keywords

Apoptosis; carcinogenesis; defective apoptotic pathways; treatment target

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BUTYRIC ACID; CASPASE; CASPASE 8; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOCHROME C; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; DEATH RECEPTOR; DEPSIPEPTIDE; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; FENRETINIDE; GOSSYPOL; HEAT SHOCK PROTEIN 90 INHIBITOR; NAVITOCLAX; NEURONAL APOPTOSIS INHIBITORY PROTEIN; OBATOCLAX; OBLIMERSEN; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SERINE PROTEINASE OMI; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; UNINDEXED DRUG; ANTINEOPLASTIC AGENT;

ALZHEIMER DISEASE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CELL DESTRUCTION; CELL MEMBRANE; CELL NUCLEUS; CELL PROLIFERATION; CELL STRUCTURE; CHROMATIN CONDENSATION; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CYTOPLASM; CYTOTOXIC T LYMPHOCYTE; DEGENERATIVE DISEASE; DNA DEGRADATION; EMBRYO DEVELOPMENT; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE SILENCING; HEAD AND NECK TUMOR; HEART INFARCTION; HUMAN; HYPOXIA; INVOLUTION; LUNG NON SMALL CELL CANCER; LYMPHOCYTE DEPLETION; MACROPHAGE; MALIGNANT TRANSFORMATION; MITOCHONDRION; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PHAGOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIATION INJURY; REVIEW; SIGNAL TRANSDUCTION; THERMAL INJURY; ANIMAL; DRUG EFFECT; PATHOLOGY; PROGNOSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; NEOPLASMS; PROGNOSIS;

EID: 80053348989     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-30-87     Document Type: Review

References (104)

1. New tricks of an old molecule: lifespan regulation by p53. Bauer JH, Hefand SL, Aging Cell 2006 5 437 440 10.1111/j.1474-9726.2006.00228.x 16968311 (Pubitemid 44322539)
2. The p53 pathway in breast cancer. Gasco M, Shami S, Crook T, Breast Cancer Res 2002 4 70 76 11879567 (Pubitemid 34248123)
3. p53 mutations in colorectal cancers. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, Lane DP, Proc Natl Acad Sci USA 1990 87 19 7555 7559 10.1073/pnas.87.19.7555 1699228
4. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, Jamieson NB, Oien KA, Lowy AM, Brunton VG, Frame MC, Jeffry Evans TR, Sansom OJ, PNAS 2010 107 1 246 251 10.1073/pnas.0908428107 20018721
5. Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukaemia. Jensen M, Engert A, Weissinger F, Knauf W, Kimby E, Poynton C, Oliff IA, Rummel MJ, sterborg A, Invest New Drugs 2008 26 2 139 149 10.1007/s10637-007-9106-z 18094935
6. The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-B/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis. Baritaki S, Militello L, Malaponte G, Spandidos DA, Salcedo M, Bonavida B, Int J Oncol 2011 38 6 1683 1694 21455568
7. Definition and incidence of apoptosis: an historical perspective. Kerr JF, Harmon BV, Apoptosis: the molecular basis of cell death New York: Cold Spring Harbor Laboratory Press, Tomei LD, Cope FO, 1991 3 5 29
8. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Kerr JFR, Wyllie AH, Currie AR, Br J Cancer 1972 26 239 257 10.1038/bjc.1972.33 4561027
9. Mohan H, Textbook of pathology New Delhi: Jaypee Brothers Medical Publishers 5 2010 21 60
10. Cellular adaptation, injury, and death. Merkle CJ, Pathophysiology: concepts of altered health states Philadelphia: Wolters Kluwer/Lippincott Williams and Wilkins, Porth CM, Matfin G, 8 2009 94 111
11. The morphology of apoptosis. Hacker G, Cell Tissue Res 2000 301 5 17 10.1007/s004410000193 10928277 (Pubitemid 30459851)
12. Morphologic and biochemical hallmarks of apoptosis. Saraste A, Pulkki K, Cardiovascular Res 2000 45 528 537 10.1016/S0008-6363(99)00384-3 (Pubitemid 30047119)
13. Morphological features of cell death. Ziegler U, Groscurth P, News Physiol Sci 2004 19 124 128 10.1152/nips.01519.2004 15143207
14. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Kroemer G, El-Deiry WS, Golstein P, Peter ME, Vaux D, Vandenabeele P, Zhivotovsky B, Blagosklonny MV, Malorni W, Knight RA, Piacentini M, Nagata S, Melino G, Cell Death Differ 2005 12 1463 1467 16247491 (Pubitemid 41553979)
15. Apoptosis, oncosis, and necrosis. An overview of cell death. Manjo G, Joris I, Am J Pathol 1995 146 3 15 7856735
16. Kumar V, Abbas AK, Fausto N, Aster JC, Robins and Cotran: pathologic basis of disease Philadelphia: Saunders Elsevier 8 2010 25 32
17. Apoptosis: corralling the corpses. Hengartner MO, Cell 2000 104 325 328 (Pubitemid 32206452)
18. Mammalian mitochondrial IAP-binding proteins. Vaux D, Silke J, Biochem Biophy Res Commun 2003 203 449 504
19. Methods for detecting and quantifying apoptosis. McCarthy NJ, Evan GI, Curr Top Dev Biol 1998 36 259 278 9342533
20. Caspases: pharmacological manipulation of cell death. Lavrik IN, Golks A, Krammer PH, J Clin Invest 2005 115 2665 2672 10.1172/JCI26252 16200200 (Pubitemid 41434390)
21. Cell death modalities: classification and pathophysiological implications. Galluzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L, Kroemer G, Cell Death Differ 2007 14 1237 1266 10.1038/sj.cdd.4402148 17431418 (Pubitemid 46969863)
22. Apoptosis: a review of pro-apoptotic and anti-apoptotic pathways and dysregulation in disease. O'Brien MA, Kirby R, J Vet Emerg Crit Care 2008 18 6 572 585 10.1111/j.1476-4431.2008.00363.x
23. Apoptosis induced by death receptors. Schneider P, Tschopp J, Pharm Acta Helv 2000 74 281 286 10.1016/S0031-6865(99)00038-2 10812970 (Pubitemid 30182582)
24. Karp G, Cell and molecular biology: Concepts and experiments John New Jersey: Wiley and Sons 5 2008 653 657
25. Cell death: critical control points. Danial NN, Korsmeyer SJ, Cell 2004 116 2 205 219 10.1016/S0092-8674(04)00046-7 14744432 (Pubitemid 38167313)
26. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14; 18) chromosome translocation. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM, Science 1984 226 1097 1099 10.1126/science.6093263 6093263 (Pubitemid 15217831)
27. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in haematologic malignancies. Reed JC, Semin Haematol 1997 34 9 19 (Pubitemid 28032415)
28. Mitochondrial membrane permeabilisation in cell death. Kroemer G, Galluzzi L, Brenner C, Physiol Rev 2007 87 1 99 163 10.1152/physrev.00013.2006 17237344 (Pubitemid 46209992)
29. IAP-targeted therapies for cancer. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG, Oncogene 2008 27 48 6252 6275 10.1038/onc.2008.302 18931692
30. Targeting apoptosis pathways in cancer therapy. Ghobrial IM, Witzig TE, Adjei AA, CA Cancer J Clin 2005 55 178 194 10.3322/canjclin.55.3.178 15890640 (Pubitemid 40826487)
31. Caspase-12 and ER stress mediated apoptosis: the story so far. Szegezdi E, Fitzgerald U, Samali, Ann NY Acad Sci 2003 1010 186 194 10.1196/annals.1299. 032 15033718 (Pubitemid 38264973)
32. The hallmarks of cancer. Hanahan D, Weinberg RA, Cell 2000 100 57 70 10.1016/S0092-8674(00)81683-9 10647931 (Pubitemid 30046295)
33. BCL-2 family members and the mitochondria in apoptosis. Gross A, McDonnell JM, Korsmeyer SJ, Genes Dev 1999 13 1899 1911 10.1101/gad.13.15.1899 10444588 (Pubitemid 29407357)
34. Bcl-x(L) forms an ion channel in synthetic lipid membranes. Minn AJ, Vélez P, Schendel SL, Liang H, Muchmore SW, Fesik SW, Fill M, Thompson CB, Nature 1997 385 6614 353 357 10.1038/385353a0 9002522 (Pubitemid 27053107)
35. Bcl-2 family-regulated apoptosis in health and disease. Dewson G, Kluc RM, Cell Health and Cytoskeleton 2010 2 9 22
36. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R, Cancer Res 1995 55 4438 7671257
37. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Fulda S, Meyer E, Debatin KM, Oncogene 2000 21 2283 2294
38. Expression of Bcl-XL can confer a multidrug resistance phenotype. Minn AJ, Rudin CM, Boise LH, Thompson CB, Blood 1995 86 1903 1910 7655019
39. Role of bax mutations in apoptosis in colorectal cancers with microsatellite instability. Miquel C, Borrini F, Grandjouan S, Aupérin A, Viguier J, Velasco V, Duvillard P, Praz F, Sabourin JC, Am J Clin Pathol 2005 23 4 562 570 (Pubitemid 40418551)
40. Bcl-2 regulatory pathway is functional in chronic lymphocytic leukaemia. Goolsby C, Paniagua M, Tallman M, Gartenhaus RB, Cytometry B Clin Cytom 2005 63 1 36 46 15624202 (Pubitemid 40096843)
41. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Pepper C, Hoy T, Bentley DP, Br J Cancer 1997 76 7 935 938 10.1038/bjc.1997.487 9328155 (Pubitemid 27401947)
42. The p53 tumour suppressor gene. Levine AJ, Momand J, Finlay CA, Nature 1991 351 6326 453 456 10.1038/351453a0 2046748 (Pubitemid 21896613)
43. p53: structure, function and therapeutic applications. Bai L, Zhu WG, J Cancer Mol 2006 2 4 141 153
44. Introduction: p53 - the first twenty years. Oren M, Rotter V, Cell Mol Life Sci 1999 55 9 11 10.1007/s000180050265 10065147 (Pubitemid 29077850)
45. p53, guardian of the genome. Lane DP, Nature 1992 358 15 16 10.1038/358015a0 1614522
46. p53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. Avery-Kiejda KA, Bowden NA, Croft AJ, Scurr LL, Kairupan CF, Ashton KA, Talseth-Palmer BA, Rizos H, Zhang XD, Scott RJ, Hersey P, BMC Cancer 2011 11 203 10.1186/1471-2407-11-203 21615965
47. Hyperproliferation, cancer, and inflammation in mice expressing a 133p53-like isoform. Slatter TL, Hung N, Campbell H, Rubio C, Mehta R, Renshaw P, Williams G, Wilson M, Engelmann A, Jeffs A, Royds JA, Baird MA, Braithwaite AW, Blood 2011 117 19 5166 5177 10.1182/blood-2010-11-321851 21411755
48. Cancer-derived p53 mutants suppress p53-target gene expression - potential mechanism for gain of function of mutant p53. Vikhanskaya F, Lee MK, Mazzoletti M, Broggini M, Sabapathy K, Nucl Acids Res 2007 35 6 2093 2104 10.1093/nar/gkm099 17344317 (Pubitemid 47061674)
49. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Vucic D, Fairbrother WJ, Clin Cancer Res 2007 13 20 5995 6000 10.1158/1078-0432.CCR-07-0729 17947460 (Pubitemid 350075054)
50. Inhibitor of apoptosis proteins and apoptosis. Wei Y, Fan T, Yu M, Acta Biochim Biophys Sin 2008 40 4 278 288 10.1111/j.1745-7270.2008.00407.x 18401525 (Pubitemid 351572108)
51. Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy. Lopes RB, Gangeswaran R, McNeish IA, Wang Y, Lemoine NR, Int J Cancer 2007 120 11 2344 2352 10.1002/ijc.22554 17311258 (Pubitemid 46642120)
52. MLIAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS, Dixit VM, Curr Biol 2000 10 1359 1366 10.1016/S0960-9822(00)00781-8 11084335
53. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. Ashhab Y, Alian A, Polliack A, Panet A, Ben Yehuda D, FEBS Lett 2001 495 56 60 10.1016/S0014- 5793(01)02366-3 11322947 (Pubitemid 32367973)
54. A human IAP-family gene, apollon, expressed in human brain cancer cells. Chen Z, Naito M, Hori S, Mashima T, Yamori T, Tsuruo T, Biochem Biophys Res Commun 1999 264 847 854 10.1006/bbrc.1999.1585 10544019
55. Overexpression of survivin initiates haematologic malignancies in vivo. Small S, Keerthivasan G, Huang Z, Gurbuxani S, Crispino JD, Leukaemia 2010 24 11 1920 1926 10.1038/leu.2010.198
56. Increased expression of inhibitor of apoptosis proteins, Survivin and XIAP, in non-small cell lung carcinoma. Krepela E, Dankova P, Moravcikova E, Krepelova A, Prochazka J, Cermak J, Schützner J, Zatloukal P, Benkova K, Int J Oncol 2009 35 6 1449 1462 19885569
57. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Fink SL, Cookson BT, Infect Immun 2005 73 4 1907 1916 10.1128/IAI.73.4.1907-1916.2005 15784530 (Pubitemid 40470787)
58. Downregulation of caspase-9 is a frequent event in patients with stage II colorectal cancer and correlates with poor clinical outcome. Shen XG, Wang C, Li Y, Wang L, Zhou B, Xu B, Jiang X, Zhou ZG, Sun XF, Colorectal Dis 2010 12 12 1213 1218 10.1111/j.1463-1318.2009.02009.x 19604285
59. Downregulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Devarajan E, Sahin AA, Chen JS, Krishnamurthy RR, Aggarwal N, Brun AM, Sapino A, Zhang F, Sharma D, Yang XH, Tora AD, Mehta K, Oncogene 2002 21 57 8843 8851 10.1038/sj.onc.1206044 12483536 (Pubitemid 36132404)
60. Caspase activity is downregulated in choriocarcinoma: a cDNA array differential expression study. Fong PC, Xue WC, Ngan HYS, Chiu PM, Chan KYK, Tsao GSW, Cheung ANY, J Clin Pathol 2006 59 2 179 183 10.1136/jcp.2005.028027 16443735 (Pubitemid 43235584)
61. Death receptor signaling. Lavrik I, Golks A, Krammer PH, J Cell Sci 2005 118 265 267 10.1242/jcs.01610 15654015 (Pubitemid 40277339)
62. Deficient activation of the CD95 (APO-1/Fas) system in drug resistant cells. Friesen C, Fulda S, Debatin KM, Leukaemia 1997 11 11 1833 1841 10.1038/sj.leu.2400827 (Pubitemid 27485127)
63. Chemosensitivity of solid tumour cells in vitro is related to activation of the CD95 system. Fulda S, Los M, Friesen C, Debatin KM, Int J Cancer 1998 76 1 105 114 10.1002/(SICI)1097-0215(19980330)76:1<105::AID-IJC17>3.0.CO;2-B 9533769 (Pubitemid 28164576)
64. Evasion of apoptosis as a cellular stress response in cancer. Fulda S, Int J Cell Biol 2010 2010 370835 20182539
65. Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Reesink-Peters N, Hougardy BM, van den Heuvel FA, Ten Hoor KA, Hollema H, Boezen HM, de Vries EG, de Jong S, van der Zee AG, Gynaecol Oncol 2005 96 3 705 713 10.1016/j.ygyno.2004.10.046 (Pubitemid 40255490)
66. Effect of the addition of oblimersen (Bcl-2 antisense) to fludarabine/cyclophosphamide for replased/refractory chronic lymphocytic leukaemia (CLL) on survival in patients who achieve CR/nPR: Five-year follow-up from a randomized phase III study [abstract]. Rai KR, Moore J, Wu J, Novick SC, O'Brien SM, J Clin Oncol 2008 26 7008
67. Novel agents for the treatment of chronic lymphocytic leukaemia. Abou-Nassar K, Brown JR, Clin Adv Haematol Oncol 2010 8 12 886 895
68. Targeting mitochondrial apoptotic pathways in cancer therapy. Kang MH, Reynolds CP, Bcl-2 inhibitors, Clin Cancer Res 2009 15 1126 1132 10.1158/1078-0432.CCR-08-0144 19228717
69. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH, Nature 2005 435 7042 677 681 10.1038/nature03579 15902208 (Pubitemid 40825512)
70. Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and upregulating BH3-only protein NOXA. Albershardt TC, Salerni BL, Soderquist RS, Bates DJ, Pletnev AA, Kisselev AF, Eastman A, J Biol Chem 2011 286 28 24882 24895 10.1074/jbc.M111.255828 21628457
71. Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Ocker M, Neureiter D, Lueders M, Zopf S, Ganslmayer M, Hahn EG, Herold C, Schuppan D, Gut 2005 54 9 1298 1308 10.1136/gut.2004.056192 16099798 (Pubitemid 41192493)
72. Silencing of Bmi-1 gene by RNA interference enhances sensitivity to doxorubicin in breast cancer cells. Wu X, Liu X, Sengupta J, Bu Y, Yi F, Wang C, Shi Y, Zhu Y, Jiao Q, Song F, Indian J Exp Biol 2011 49 2 105 112 21428211
73. Retrovirus-mediated wild-type p53 gene transfer to tumuors of patients with lung cancer. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KM, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han CI, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T, Cai D, Nature Medicine 1996 2 9 985 991 10.1038/nm0996-985 8782455 (Pubitemid 26306836)
74. p53 as a drug target in cancer therapy. Chène P, Expert Opin Ther Patents 2001 11 6 923 935 10.1517/13543776.11.6.923 (Pubitemid 32536829)
75. Recent advances in p53 research and cancer treatment. Suzuki K, Matusubara H, J Biomed Biotech 2011 2011 978312
76. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. John Nemunaitis, Ian Ganly, Fadlo Khuri, James Arseneau, Joseph Kuhn, Todd McCarty, Stephen Landers, Phillip Maples, Larry Rome, Britta Randlev, Tony Reid, Sam Kaye, David Kirn, Cancer Res 2000 60 6359 11103798
77. Targeted rescue of a destabilised mutant of p53 by an in silico screened drug. Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR, Proc Natl Acad Sci USA 2008 105 30 10360 10365 10.1073/pnas.0805326105 18650397
78. Characterisation of the p53-rescue drug CP-31398 in vitro and in living cells. Rippin TM, Bykov VJ, Freund SM, Selivanova G, Wiman KG, Fersht A, Oncogene 2002 21 14 2119 2129 10.1038/sj.onc.1205362 11948395 (Pubitemid 34311366)
79. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Shangary S, Wang S, Annu Rev Pharmacol Toxicol 2008 49 223 241
80. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumours and leads to complete tumor growth inhibition. Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S, Nikolovska-Coleska Z, Ding K, Wang G, Chen J, Bernard D, Zhang J, Lu Y, Gu Q, Shah RB, Pienta KJ, Ling X, Kang S, Guo M, Sun Y, Yang D, Wang, Proc Natl Acad Sci USA 2008 105 10 3933 3938 10.1073/pnas.0708917105 18316739 (Pubitemid 351723502)
81. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, McCarthy A, Appleyard V, Murray KE, Baker L, Thompson A, Mathers J, Holland SJ, Stark MJ, Pass G, Woods J, Lane DP, Westwood NJ, Cancer Cell 2008 13 5 454 463 10.1016/j.ccr.2008.03.004 18455128 (Pubitemid 351609441)
82. Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man. Kuball J, Schuler M, Antunes Ferreira E, Herr W, Neumann M, Obenauer-Kutner L, Westreich L, Huber C, Wölfel T, Theobald M, Gene Ther 2002 9 13 833 843 12080377 (Pubitemid 34716327)
83. Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Svane IM, Pedersen AE, Johnsen HE, Nielsen D, Kamby C, Gaarsdal E, Nikolajsen K, Buus S, Claesson MH, Cancer Immunol Immunother 2004 53 7 633 641 10.1007/s00262-003-0493-5 14985857 (Pubitemid 38858337)
84. Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies. Vermeij R, Leffers N, van der Burg SH, Melief CJ, Daemen T, Nijman HW, J Biomed Biotechnol 2011 2011 702146 21541192
85. Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B. Dai Y, Lawrence TS, Xu L, Am J Tranl Res 2009 1 1 1 15
86. XIAP and Survivin as therapeutic targets for radiation sensitisation in preclinical models of lung cancer. Cao C, Mu Y, Hallahan DE, Lu B, Oncogene 2004 23 7047 7052 10.1038/sj.onc.1207929 15258565 (Pubitemid 39319166)
87. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, Mayer LD, LaCasse EC, Clin Cancer Res 2003 9 2826 2836 12855663 (Pubitemid 36842129)
88. siRNA targeting NBS1 or XIAP increases radiation sensitivity of human cancer cells independent of TP53 status. Ohnishi K, Scuric Z, Schiesti RH, Okamoto N, Takahashi A, Ohnishi T, Radiat Res 2006 166 454 462 10.1667/RR3606.1 16972754 (Pubitemid 44353428)
89. Targeting of X-linked inhibitor of apoptosis protein or Survivin by short interfering RNAs sensitises hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death. Yamaguchi Y, Shiraki K, Fuke H, Inoue T, Miyashita K, Yamanaka Y, Saitou Y, Sugimoto K, Nakano T, Oncol Rep 2005 12 1211 1316
90. Expression and targeting of the apoptosis inhibitor, Survivin, in human melanoma. Grossman D, McNiff JM, Li F, Altieri DC, J Invest Dermatol 1999 113 6 1076 1081 10.1046/j.1523-1747.1999.00776.x 10594755 (Pubitemid 30013356)
91. Antisense-mediated downregulation of antiapoptotic proteins induces apoptosis and sensitises head and neck squamous cell carcinoma cells to chemotherapy. Sharma H, Sen S, Lo ML Mraiggi Singh N, Cancer Biol Ther 2005 4 720 727 10.4161/cbt.4.7.1783 15917659 (Pubitemid 41351170)
92. Antisurvivin oligonucleotides inhibit growth and induce apoptosis in human medullary thyroid carcinoma cells. Du ZX, Zhang HY, Gao DX, Wang HQ, Li YJ, Liu GL, Exp Mol Med 2006 38 230 240 16819281
93. Downregulation of Survivin by siRNA diminishes radioresistance of pancreatic cancer cells. Kami K, Doi R, Koizumi M, Toyoda E, Mori T, Ito D, Kawaguchi Y, Fujimoto K, Wada M, Miyatake S, Imamura M, Surgery 2005 138 2 299 305 10.1016/j.surg.2005.05.009 16153440 (Pubitemid 41253814)
94. Inhibitory effects of the survivin siRNA transfection on human lung adenocarcinoma cells SPCA1 and SH77. Liu Q, Dong C, Li L, Sun J, Li C, Li L, Zhongguo Fei Ai Za Zhi 2011 14 1 18 22 21219826
95. Effects of Survivin siRNA on growth, apoptosis and chemosensitivity of ovarian cancer cells SKOV3/DDP. Zhang X, Li N, Wang YH, Huang Y, Xu NZ, Wu LY, Zhonghua Zhong Liu Za Zhi 2009 31 3 174 177 19615253
96. Adenovirus-mediated transfer of siRNA against Survivin enhances the radiosensitivity of human non-small cell lung cancer cells. Yang CT, Li JM, Weng HH, Li YC, Chen HC, Chen MF, Cancer Gene Ther 2010 17 120 130 10.1038/cgt.2009.55 19730451
97. Targeting Survivin in cancer therapy: fulfilled promises and open questions. Pennati M, Folini M, Zaffaroni N, Carcinogenesis 2007 28 6 1133 1139 10.1093/carcin/bgm047 17341657 (Pubitemid 47062670)
98. Cyclopeptide Smac mimetics as antagonists of IAP proteins. Sun H, Liu L, Lu J, Qiu S, Yang CY, Yi H, Wang S, Bioorg Med Chem Lett 2010 20 10 3043 3046 10.1016/j.bmcl.2010.03.114 20443226
99. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. Lu J, McEachern D, Sun H, Bai L, Peng Y, Qiu S, Miller R, Liao J, Yi H, Liu M, Bellail A, Hao C, Sun SY, Ting AT, Wang S, Mol Cancer Ther 2011 10 5 902 914 10.1158/1535-7163.MCT-10-0864 21372226
100. The viral death effector Apoptin reveals tumour-specific processes. Rohn JL, Noteborn MH, Apoptosis 2004 9 315 322 15258463 (Pubitemid 38981505)
101. Caspases and cancer: mechanisms of inactivation and new treatment modalities. Philchenkov A, Zavelevich M, Kroczak TJ, Los M, Exp Oncol 2004 26 2 82 97 15273659
102. Cancer gene therapy using a pro-apoptotic gene, caspase-3. Yamabe K, Shimizu S, Ito T, Yoshioka Y, Nomura M, Narita M, Saito I, Kanegae Y, Matsuda H, Gene Ther 1999 6 12 1952 1959 10.1038/sj.gt.3301041 10637446 (Pubitemid 30076865)
103. Gene transfer of constitutively active caspase-3 induces apoptosis in a human hepatoma cell line. Cam L, Boucquey A, Coulomb-L'hermine A, Weber A, Horellou P, J Gene Med 2005 7 1 30 38 10.1002/jgm.636 15521050
104. Inhibitory effect of recombinant adenovirus carrying immunocaspase-3 on hepatocellular carcinoma. Li X, Fan R, Zou X, Gao L, Jin H, Du R, Xia L, Fan D, Biochem Bioohys Res Commun 2007 358 2 489 494 10.1016/j.bbrc.2007.04.134 (Pubitemid 46755731)